The number of available grafts for liver transplantation (LT) has failed to keep pace with the needs of the recipient pool of patients. Thus, extending the donor pool remains a critical concern. There are several forms of extended criteria donors who can provide more grafts but the grafts are marginal. Steatosis is considered one of the most widely represented marginal grafts because of the worldwide increasing prevalence of nonalcoholic fatty liver diseases. [@JR1800010oa-1]

Liver steatosis is subdivided qualitatively into macrosteatosis (MaS) and microsteatosis (MiS). MaS is characterized by a single fat vacuole in hepatocytes, displacing the nucleus to the edge of the cell. In MiS, the cytoplasm of the hepatocytes contains tiny lipid vesicles without nuclear dislocation. Steatosis is further classified quantitatively into mild, moderate, or severe if (≥5 to \< 30%), (≥30 to ≤60%), or (\> 60%) of hepatocytes, respectively, display fatty infiltrations. [@JR1800010oa-2]

Despite their benign nature, fatty livers may be associated with serious injury including inflammation and hepatocyte necroapoptosis. [@JR1800010oa-3] In the past, grafts with ≥30% fatty infiltration were not acceptable for transplantation. Furthermore, the use of livers with less fatty infiltration (\< 30%) has been reported to result in bad outcomes after LT. [@JR1800010oa-4] Recently, some authors reported excellent results after transplantation using severely steatotic livers but with a lower model for end-stage liver disease (MELD) score and shorter ischemia times. [@JR1800010oa-5] [@JR1800010oa-6] [@JR1800010oa-7] [@JR1800010oa-8]

Great diversity exists in regard to the impact of the type of steatosis on post LT outcomes. Some authors regard MaS to be more clinically relevant than MiS [@JR1800010oa-9] [@JR1800010oa-10] while others consider MiS to be an independent risk factor that can affect the early function of the graft. [@JR1800010oa-11] Cieślak et al observed that a 12% increase in MiS was equivalent to a 50% increased risk for postoperative graft dysfunction. [@JR1800010oa-12]

Therefore, our aim was to evaluate the impact of graft steatosis on post LT outcomes.

Methods
=======

Study Design
------------

This study is a retrospective cohort study that was a collaboration between Sohag University, Egypt and Polytechnic University of Marche, Italy. Ethical committee approval for the study was obtained with the No. 0113150/02--14. All patients provided informed written consent prior to the transplant procedures and transplant waiting list inclusion. The study protocol was registered at ClinicalTrials.gov as NCT02659553. The study was performed utilizing the "Strengthening the Reporting of Cohort Studies in Surgery (STROCSS)" statement. [@JR1800010oa-13]

Setting and Participants
------------------------

The study was conducted at the Division of Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy. The study included the transplanted cases from August 2005 to April 2016 that matched the eligibility criteria.

### Eligibility Criteria

All adult patients who underwent primary LT with a preoperative histopathological report of the donor graft determining the type and degree of fatty infiltration were included in this study. Retransplanted patients and patients with no preoperative determination of the type and/or degree of graft steatosis were excluded from the study.

### Data Collection

The patients\' records of 271 recipients that matched our eligibility criteria were analyzed for any postoperative complications during the primary hospital stay (from the date of LT to the date of discharge). Overall complications during the first 6 postoperative months and long-term patient and graft survivals were also studied.

The severity of the liver disease of the recipients was assessed by MELD score. ABO blood group compatible grafts from deceased heart-beating donors with accepted liver function tests were used for all participants. Organ procurement was performed according to the standard techniques with the back-table preparation of the graft. A graft biopsy was obtained using a true-cut needle at the time of procurement. Grafts were preserved using Celsior ( *n*  = 262), University of Wisconsin ( *n*  = 8), or Histidine-Tryptophan-Ketoglutarate ( *n*  = 1) solutions and placed on ice.

Recipient total hepatectomy followed by LT using the conventional ( *n*  = 19), piggyback ( *n*  = 247), or piggyback variant ( *n*  = 5) technique was performed. Then, end-to-end porto-portal vein (porto-PV) anastomosis ( *n*  = 266), the cavoportal hemitransposition technique ( *n*  = 3), or bypass porto-mesenteric anastomosis ( *n*  = 2) was performed. The hepatic arterial circulation was maintained through end-to-end hepatic artery anastomosis ( *n*  = 247), celiac--hepatic ( *n*  = 6), celiac--celiac ( *n*  = 2), celiac--aortic ( *n*  = 6), or hepatic--aortic anastomosis ( *n*  = 10). Biliary reconstruction was performed by end-to-end choledochocholedochostomy ( *n*  = 257) or hepaticojejunostomy ( *n*  = 14).

In our institution, 500 mg of steroids plus 20 mg of basiliximab were administered at the time of perfusion. Then, postoperative immunosuppressive schemes were tailored for each patient but they were predominantly based on steroids, tacrolimus, and/or basiliximab.

During the hospital stay, postoperative graft follow-up was achieved by daily measurements of transaminases, albumin, bilirubin, and the international normalized ratio (INR). A duplex examination was performed routinely every day for the first postoperative week, then every other day until hospital discharge, then monthly for the first year. A postoperative graft biopsy was not routinely done in our center except when there was clinical or biochemical evidence of graft dysfunction.

Study Variables and Measurements
--------------------------------

Steatosis was considered the factor of interest in this study. Qualitatively patients were divided into two categories: MaS or MiS. Each category was subdivided quantitatively into three groups: control group with no steatosis (\< 5%), compared with mild (≥5 to \< 30%), and moderate (≥30 to ≤60%) steatosis.

These groups were analyzed for any major postoperative negative outcomes during the hospital stay based on the Clavien--Dindo classification with definitions specified for LT. [@JR1800010oa-14] [@JR1800010oa-15] Other outcomes of interest included primary nonfunction (PNF), early graft dysfunction (EGD), acute cellular rejection (ACR), biliary complications, and patient and graft survivals.

PNF was defined as graft failure soon after reperfusion without an obvious cause leading to either retransplantation or death in the first postoperative week. It was diagnosed by (1) an increased aspartate transaminase (AST) level ≥3,000 U/L and (2) INR ≥2.5 and/or acidosis (arterial pH ≤7.30 or venous pH ≤7.25 and/or lactate ≥4 mmol/L). [@OR1800010oa-16]

EGD was defined as impaired initial graft function with a high peak serum transaminase and persistently high bilirubin levels. It was diagnosed by measurement of one or more of the following values: bilirubin ≥10 mg/dL on day 7, INR ≥1.6 on day 7, and AST \> 2,000 IU/L within the first 7 days. [@JR1800010oa-17]

ACR was broadly defined as graft inflammation elicited by genetic disparity between the donor and recipient. Graft biopsy, obtained using a true-cut needle, remains the gold standard for ACR diagnosis. [@JR1800010oa-18]

Bile leakage is defined as a fluid with an increased bilirubin concentration (three times greater than the serum bilirubin measured at the same time) in the abdominal drain or in the intra-abdominal fluid on or after postoperative day (POD) 3 or as the need for radiologic intervention or relaparotomy. [@JR1800010oa-19] Biliary stricture is an abnormal narrowing of the bile duct associated with rising cholestasis indexes that required invasive management, such as endoscopic retrograde cholangiopancreatography, percutaneous transhepatic drainage, or resurgery. [@JR1800010oa-20]

Acute postoperative vascular complications including portal vein thrombosis (PVT), hepatic artery thrombosis (HAT), and haemoperitoneum were studied. Postoperative ascites, renal insufficiency, hepatitis C virus (HCV) recurrence, and intensive care unit (ICU) and hospital stays were also evaluated.

Patient survival was calculated from the date of transplantation to the date of patient death. Graft survival was calculated from the date of transplantation to the date of irreversible graft failure, retransplantation, or the date of death.

Bias Assessment
---------------

All records were independently reviewed by the endpoint assessment committee which included certified surgeons and gastroenterologists. All members of the end point assessment committee were blinded to the study participants\' baseline risk factor information.

Statistical Analysis
--------------------

Continuous variables were presented as the means and standard deviation while categorical variables were expressed as percentages. Quantitative variables were compared using a one-way ANOVA (analysis of variance) test. For qualitative variables, Pearson\'s Chi-square tests were used after assumptions had been verified. A 95% confidence interval (CI) was reported for both measures. Graft and patient survival rates were described and compared using a Kaplan--Meier test. A *p* -value \< 0.05 was considered statistically significant. All statistical tests were performed using IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp, Version 20.

Results
=======

Participants and Descriptive Data
---------------------------------

From August 2005 to April 2016, 271 cases matched our inclusion and exclusion criteria and were included in this study. The primary indications for LT in the selected patients are shown in [Table 1](#TB1800010oa-1){ref-type="table"} and included end-stage liver disease due to hepatitis ( *n*  = 178), alcoholism ( *n*  = 45), or other ( *n*  = 46), and/or HCC (hepatocellular carcinoma; *n*  = 103), cholangiocarcinoma ( *n*  = 1), or complicated adenoma ( *n*  = 1). To the best of our knowledge, all cases of HCC were associated with a different liver pathology. Regarding the type and degree of graft steatosis, 125 patients received grafts with MaS of which 109 were mild and 16 were moderate. Additionally, 96 patients received grafts with MiS of which 77 were mild and 19 were moderate. The clinicopathological features of the donors and recipients are listed in [Table 1](#TB1800010oa-1){ref-type="table"} .

###### Demographic and clinicopathological criteria of all participants

  Type of steatosis                  Macrosteatosis ( *n*  = 271)   Microsteatosis ( *n*  = 271)                                                                             
  ---------------------------------- ------------------------------ ------------------------------ --------------- ------- ----------------- --------------- --------------- -------
  Donor criteria ( *n*  = 271)                                                                                                                                               
  Age (y)                            60.9 ± 17.74                   64.3 ± 14.26                   57.2 ± 17.37    0.126   61.36 ± 17.00     65.35 ± 13.65   55.00 ± 19.62   0.031
  Sex (m/f)                          75/71                          62/47                          10/6            0.540   99/76             38/39           10/9            0.564
  D-MELD score                       1,100 ± 643                    1,127.6 ± 600                  740.9 ± 396.9   0.062   1,073.7 ± 625.7   1,182.8 ± 615   863 ± 518.7     0.110
  DRI                                1.86 ± 0.59                    1.95 ± 0.75                    1.68 ± 0.38     0.261   1.89 ± 0.64       1.92 ± 0.70     1.60 ± 0.40     0.162
  BMI (kg/m ^2^ )                    25.38 ± 3.01                   27.16 ± 4.25                   27.87 ± 4.21    0.000   26.24 ± 3.96      26.28 ± 3.36    26.15 ± 3.28    0.991
  ALT (U/L)                          47.28 ± 64.06                  39.52 ± 42.75                  50.4 ± 50.07    0.513   44.61 ± 56.75     40.03 ± 46.39   59.89 ± 77.56   0.401
  AST (U/L)                          49.8 ± 64.75                   47.36 ± 52.9                   68.0 ± 93.38    0.490   48.92 ± 62.24     47.45 ± 55.8    68.56 ± 84.54   0.416
  PT-INR                             3.73 ± 16.9                    4.05 ± 17.05                   1.21 ± 0.26     0.845   4.89 ± 20.12      1.44 ± 1.26     1.29 ± 0.15     0.327
  Na                                 150.05 ± 9.71                  150.2 ± 9.08                   148.9 ± 10.9    0.880   149.73 ± 9.48     150.54 ± 9.65   151.12 ± 9.45   0.743
  ICU stay (d)                       4.67 ± 4.19                    4.67 ± 4.35                    4.4 ± 3.38      0.972   4.69 ± 4.22       4.73 ± 4.35     4.05 ± 3.55     0.810
  Cause of death                                                                                                                                                             
   Cerebral hemorrhage               91 (62.3)                      65 (59.6)                      7 (43.8)        0.868   106 (60.6)        48 (62.3)       9 (47.4)        0.908
   Cranial trauma                    29 (19.9)                      23 (21.1)                      7 (43.8)        0.868   36 (20.6)         15 (19.5)       8 (42)          0.908
   Brain anoxia                      13 (8.9)                       10 (9.2)                       1 (6.2)         0.868   16 (9)            6 (7.8)         2 (10.5)        0.908
   Ischemic stroke                   9 (6.2)                        9 (8.3)                        1 (6.2)         0.868   11 (6.3)          8 (10.4)        0 (0)           0.908
   Others                            4 (2.7)                        2 (1.8)                        0 (0)           0.868   6 (3.4)           0 (0)           0 (0)           0.908
  Recipient criteria ( *n*  = 271)                                                                                                                                           
  Age (y)                            53.84 ± 8.35                   52.53 ± 9.39                   56.75 ± 6.68    0.152   53.62 ± 8.62      53.35 ± 8.99    52.74 ± 9.12    0.905
  Sex (m/f)                          111/35                         83/26                          11/5            0.803   131/44            58/19           16/3            0.664
  MELD score                         17.84 ± 8.25                   16.09 ± 7.49                   19.50 ± 7.22    0.110   17.34 ± 7.99      17.26 ± 7.56    16.16 ± 9.12    0.828
  BMI (kg/m ^2^ )                    24.71 ± 3.99                   25.1 ± 4.23                    25.37 ± 3.54    0.678   25.30 ± 4.25      24.03 ± 3.47    24.84 ± 3.99    0.072
  Indications of LT                                                                                                                                                          
   HCV                               69 (47.3)                      54 (49.5)                      7 (43.4)        0.830   88 (50.3)         37 (48)         5 (26.3)        0.445
   Plus, HCC                         55 (37.7)                      40 (36.7)                      8 (50)          0.830   71 (40.6)         27 (35)         5 (26.3)        0.445
   Alcoholic                         25 (17)                        15 (13.8)                      5 (31.3)        0.830   28 (16)           12 (15.6)       5 (26.3)        0.445
   Cryptogenic                       13 (9)                         9 (8.3)                        1 (6.3)         0.830   16 (9)            6 (7.8)         1 (5.3)         0.445
   HBV                               12 (8)                         10 (9.2)                       2 (12.5)        0.830   11 (6.3)          10 (13)         3 (15.8)        0.445
   HBV--HDV                          8 (5.5)                        9 (8.3)                        0 (0)           0.830   12 (6.9)          4 (5.2)         1 (5.3)         0.445
   Cholestasis                       10 (7)                         3 (2.8)                        1 (6.3)         0.830   9 (5)             3 (3.9)         2 (10.5)        0.445
   Others                            9 (6)                          9 (8)                          0 (0)           0.830   11 (6.3)          5 (6.5)         2 (10.5)        0.445
  ALT (U/L)                          69.6 ± 94.6                    216.9 ± 1047                   43.88 ± 31.44   0.202   82.41 ± 175.4     243 ± 1,228     73.37 ± 150     0.212
  AST (U/L)                          100.9 ± 110                    297.5 ± 1410                   63.62 ± 48.3    0.205   107.8 ± 159.6     357.7 ± 1663    86.47 ± 97      0.122
  PT-INR                             5.73 ± 24.16                   5.0 ± 24.19                    1.81 ± 0.75     0.813   4.81 ± 20.42      6.83 ± 31.42    2.21 ± 2.7      0.695

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; D-MELD, donor-model end-stage liver disease; DRI, donor risk index; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus, HDV, hepatitis D virus; ICU, intensive care unit; LT, liver transplantation; PT/INR, prothrombin time/international normalized ratio.

In the MaS category, the only significant difference was in the donor body mass index (BMI) which was lower in the control group than in the mild and moderate groups (25.38 ± 3.01 vs. 27.16 ± 4.25 vs. 27.87 ± 4.21, *p*  = 0.000, respectively). Moreover, the D-MELD (donor-MELD) score was much lower in the moderate group than in the control and mild groups but the scores were not significantly different (740.94 ± 396.98 vs. 1100.07 ± 643.3 vs. 1127.6 ± 600.17, *p*  = 0.062, respectively).

In the MiS category, the only significant difference was the donor age which was markedly lower in the moderate group than in the control and mild groups (55.00 ± 19.62 vs. 61.36 ± 17.00 vs. 65.35 ± 13.65, *p*  = 0.031, respectively).

The operative parameters and ischemia times are listed in [Table 2](#TB1800010oa-2){ref-type="table"} . No differences were noted among any groups within MaS and MiS in regard to the cold ischemia time (CIT), total ischemia time (TIT), or surgical time.

###### Operative parameters of all patients

  Type of steatosis       Macrosteatosis ( *n*  = 271)   Microsteatosis ( *n*  = 271)                                                                                   
  ----------------------- ------------------------------ ------------------------------ ----------------- ------- ----------------- ----------------- ----------------- -------
  CIT (min.)              433.13 ± 113.46                414.62 ± 121.98                440.56 ± 150.08   0.419   423.16 ± 111.98   428.10 ± 130.68   445.84 ± 138.39   0.724
  WIT (min.)              32.51 ± 10.63                  43.12 ± 66.63                  44.63 ± 20.38     0.123   37.09 ± 45.89     39.13 ± 42.68     34.21 ± 11.09     0.891
  TIT (min.)              465.64 ± 114.56                457.74 ± 113.23                485.19 ± 156.5    0.650   460.25 ± 110.26   467.23 ± 124.52   480.05 ± 142.46   0.743
  Operative time (min.)   421.68 ± 79.43                 416.87 ± 90.88                 461.56 ± 108.8    0.154   426.03 ± 90.82    411.16 ± 77.87    430.79 ± 75.62    0.410

Abbreviations: CIT, cold ischemia time; TIT, total ischemia time; WIT, warm ischemia time.

Outcome Data and Main Results
-----------------------------

### Impact of Graft MaS on Post LT Outcomes

According to the Clavien--Dindo grading of in-hospital complications ( [Table 3](#TB1800010oa-3){ref-type="table"} ), a significant difference in the grade III complication rate ( *p*  = 0.019) was detected among the groups with a higher rate in the moderate group (31%) than in the control (nonsteatotic; 23%) and mild (11%) groups. This difference was also observed between the moderate ( *p*  = 0.027) and control ( *p*  = 0.012) groups when compared with the mild group separately. No significant difference was noted when comparing the moderate and control groups ( *p*  = 0.479). An increase in the grade IV complication rate was also observed in the moderate group (12.5%) compared with the control and mild groups (3.4 and 1.8%, respectively) but the difference did not reach statistical significance ( *p*  = 0.084). No significant difference was detected among the groups in regard to the grade V complication rate ( *p*  = 0.215).

###### Postoperative outcomes after liver transplantation

  Type of steatosis                                         Macrosteatosis ( *n*  = 271)   Microsteatosis ( *n*  = 271)                                                                         
  --------------------------------------------------------- ------------------------------ ------------------------------ -------------- ------- --------------- --------------- -------------- -------
  Overall complication                                                                                                                                                                          
  PNF                                                       4 (2.7)                        5 (4.6)                        1 (6.2)        0.634   5 (2.9)         5 (6.5)         0 (0.0)        0.250
  EGD                                                       49 (33.6)                      39 (35.8)                      9 (56.2)       0.199   60 (34.3)       27 (35.1)       10 (52.6)      0.282
  PVT                                                       2 (1.4)                        1 (0.9)                        0 (0.0)        0.858   3 (1.7)         0 (0.0)         0 (0.0)        0.435
  Acute HAT                                                 4 (2.7)                        4 (3.7)                        2 (12.5)       0.145   7 (4.0)         3 (3.9)         0 (0.0)        0.676
  Ascites                                                   27 (18.5)                      14 (12.8)                      2 (12.5)       0.441   26 (14.9)       15 (19.5)       2 (10.5)       0.524
  Bile leakage                                              17 (11.6)                      14 (12.8)                      0 (0.0)        0.319   13 (7.4)        12 (15.6)       2 (10.5)       0.137
  Biliary stricture                                         24 (16.4)                      17 (15.6)                      3 (18.8)       0.946   27 (15.4)       12 (15.6)       3 (15.8)       0.999
  Haemoperitoneum                                           9 (6.2)                        7 (6.4)                        1 (6.2)        0.996   9 (5.1)         6 (7.8)         2 (10.5)       0.531
  Renal failure                                             17 (11.6)                      8 (7.3)                        1 (6.2)        0.460   15 (8.6)        9 (11.7)        2 (10.5)       0.734
  ACR                                                       58 (39.7)                      35 (32)                        3 (18.8)       0.161   68 (39)         25 (32.5)       3 (15.8)       0.111
  HCV recurrence                                            14 (9.6)                       9 (8.3)                        0 (0.0)        0.423   17 (9.7)        7 (9.1)         0 (0.0)        0.366
  Retransplantation                                         6 (4)                          6 (5.5)                        0 (0.0)        0.584   8 (4.6)         3 (4)           1 (5.3)        0.955
  Hospital stay complications as graded by Clavien--Dindo                                                                                                                                       
  Grade III                                                 34 (23.3)                      12 (11)                        5 (31)         0.019   34 (19.4)       13 (17)         5 (26.3)       0.640
  Grade IV                                                  5 (3.4)                        2 (1.8)                        2 (12.5)       0.084   6 (3.4)         0 (0)           0 (0)          0.186
  Grade V                                                   12 (8.2)                       16 (14.7)                      1 (6.2)        0.215   14 (8.0)        15 (19.5)       1 (5.3)        0.020
  ICU stay (d)                                              7.81 ± 32.46                   5.25 ± 7.45                    9.2 ± 9.6      0.696   7.71 ± 29.96    5.62 ± 6.47     4.24 ± 3.47    0.765
  Hospital stay (d)                                         21.43 ± 12.64                  20.03 ± 13.44                  21.6 ± 10.76   0.719   21.33 ± 13.56   20.15 ± 11.75   19.94 ± 9.11   0.788

Abbreviations: ACR, acute cellular rejection; EGD, early graft dysfunction; HAT, hepatic artery thrombosis; HCV, hepatitis C virus; ICU, intensive care unit; PNF, primary nonfunction; PVT, portal vein thrombosis.

Regarding the overall complications encountered after LT ( [Table 3](#TB1800010oa-3){ref-type="table"} ), one patient in the moderate group (6.2%), five in the mild group (4.6%) and four in the control group (2.7%) had experienced PNF, with no statistical increase in PNF ( *p*  = 0.634). In addition, there was a higher rate of EGD and acute HAT when comparing the moderate group (56.2 and 12.5%, respectively) with the mild (35.8 and 3.7%, respectively) and control (33.6 and 2.7%, respectively) groups. Although there was a large difference in the rates of EGD and HAT, no statistical significance was observed ( *p*  = 0.199 and 0.145, respectively). Conversely, the ACR rate was higher in the control and mild groups compared with the moderate group (39.7, 32, and 18.8%, respectively) but it did not reach a significant level ( *p*  = 0.161).

Within the first postoperative 6 months, no cases of postoperative bile leakage or HCV recurrence were documented in the moderate group compared with the control (11.6 and 9.6%, respectively) and mild (12.8 and 8.3%, respectively) groups, and there was no significant difference among the groups ( *p*  = 0.319 and 0.423, respectively). Nearly equal results were obtained among all MaS groups in regard to the rates of postoperative ascites, biliary stricture, haemoperitoneum, PVT, and renal failure ( *p*  = 0.441, 0.946, 0.996, 0.858, and 0.460, respectively).

As described in [Table 4](#TB1800010oa-4){ref-type="table"} , there were no significant differences among the 1-, 3-, and 5-year patient and graft survivals among the MaS groups ( *p*  = 0.184 and 0.262, respectively). Survival plots of patient and graft survivals are shown in [Figs. 1](#FI1800010oa-1){ref-type="fig"} and [2](#FI1800010oa-2){ref-type="fig"} , respectively.
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###### Patients and grafts survivals

  ------------------------------------------------------------------------------------------------------------------------------------
  Type of steatosis     Macrosteatosis ( *n*  = 271)   Microsteatosis ( *n*  = 271)                                        
  --------------------- ------------------------------ ------------------------------ ----------- ------------ ----------- -----------
  Degree of steatosis   No\                            Mild\                          Moderate\   No\          Mild\       Moderate\
                        *n*  = 146                     *n*  = 109                     *n*  = 16   *n*  = 175   *n*  = 77   *n*  = 19

  Patient survival      *p*  = 0.184                   *p*  = 0.347                                                        

  1-year                83                             77                             94          84           73          89

  3-year                78                             67                             88          77           68          83

  5-year                75                             57                             81          72           61          76

  Graft survival        *p*  = 0.262                   *p*  = 0.459                                                        

  1-year                79                             77                             94          81           71          89

  3-year                75                             66                             88          75           67          83

  5-year                72                             56                             81          69           60          76
  ------------------------------------------------------------------------------------------------------------------------------------

### Impact of Graft MiS on Post LT Outcomes

As summarized in [Table 3](#TB1800010oa-3){ref-type="table"} , a significant difference was noticed in the grade V complication rate among the MiS groups ( *p*  = 0.020), with a higher rate in the mild group (19.5%) compared with the control (nonsteatotic) and moderate groups (8.0 and 5.3%, respectively). This difference emerged between the mild and control groups only ( *p*  = 0.009) with no differences found between the moderate and mild groups ( *p*  = 0.136) or the moderate and control groups ( *p*  = 0.671). No statistical differences were observed in the grade III and IV complications rate ( *p*  = 0.640 and 0.186, respectively).

Regarding the overall complications encountered after LT ( [Table 3](#TB1800010oa-3){ref-type="table"} ), five cases of PNF were observed in both the mild (6.5%) and the control (2.9%) groups, with no PNF in the moderate group. These results were not significantly different ( *p*  = 0.250). Additionally, there was a higher rate of EGD in the moderate group of patients (52.6%) than in the mild (35.1%) and control (34.3%) groups, respectively but these results were not significant ( *p*  = 0.282). Like MaS, the ACR rate was higher in the control and mild groups than in the moderate group (39, 32.5, and 15.8%, respectively) but the differences were not significant ( *p*  = 0.111).

Within the first 6 postoperative months, a higher frequency of HCV recurrence was observed in the control (9.7%) and mild (9.1%) MiS groups; no cases were observed in the moderate group ( *p*  = 0.366). Moreover, nearly equal results were obtained among all MiS groups in regard to the rates of postoperative HAT, PVT, ascites, biliary leakage, biliary strictures, haemoperitoneum, and renal failure ( *p*  = 0.676, 0.435, 0.524, 0.137, 0.999, 0.531, and 0.734, respectively).

As described in [Table 4](#TB1800010oa-4){ref-type="table"} , there were no significant differences between the 1-, 3-, and 5-year patient and graft survivals among the MiS groups ( *p*  = 0.347 and 0.459, respectively). Survival plots of patient and graft survivals are shown in [Figs. 3](#FI1800010oa-3){ref-type="fig"} and [4](#FI1800010oa-4){ref-type="fig"} , respectively.
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Discussion
==========

Several donor and recipient risk factors can contribute to post LT outcomes. Therefore in this study, the D-MELD and DRI (donor risk index) scores were carefully reviewed and found to be of lower values in cases of increased steatosis. Conversely, the recipient age and MELD score were not greatly considered in relation to the degree of steatosis. Furthermore, CIT and TIT were not considered in regard to the degree or type of steatosis, trending toward a longer duration in the moderate groups of both categories. The maximum CIT in all study groups did not exceed 10 hours.

From the results, it seems that the steatosis type or degree were not the main risk factors for post LT complication rate. Additionally, Wong et al demonstrated no significant difference in grade III, IV, and V complications between severely steatotic grafts versus a control group. [@JR1800010oa-7] Moreover, Westerkamp et al reported a significant increase only in the grade IV complication rate in a moderate MaS group compared with a control group (53 vs. 13%, respectively). The majority of these complications were related to single organ failure including respiratory or renal insufficiency. [@JR1800010oa-21]

Although the rates of EGD paralleled the degree of steatosis in MaS and MiS and were the highest in the moderate groups (56.2 and 52.6%, respectively), no statistical significance was observed. Similarly, no significant differences were noted in the MaS and MiS groups in regard to postoperative PNF, retransplantation, PVT, HAT, haemoperitoneum, renal insufficiency, or ascites. Likewise, previous reports described early poor liver function and bilirubin levels in the moderate graft steatosis group within the first 2 days after LT. These undesirable outcomes became comparable with the control groups on POD 7 without any significant differences in the rates of EGD, PNF, retransplantation, or vascular complications. [@JR1800010oa-1] [@JR1800010oa-21] Conversely, a recent systematic review reported a significantly increased rate of EGD in the moderate steatosis group when compared with nonsteatotic groups. In addition, a trend toward a higher rate of PNF in these groups was described but it lacked statistical significance. [@JR1800010oa-22] Notably, this review demonstrated that there were large heterogeneities among the included studies in regard to the definition of PNF and EGD. Additionally, the studies that showed these significant results had few participants.

With regard to biliary complications, Frongillo et al reported an increased incidence of ischemia time biliary lesions in a mild/moderate group of steatosis. [@JR1800010oa-23] In line with this report, an Italian multicentre study concluded that MaS \> 25% was an independent risk factor for predicting posttransplant biliary complications. [@JR1800010oa-24] Both studies attributed these results to the compression of the hepatic sinusoidal space by fatty vacuoles, causing partial, or complete obstruction with a subsequent compromise of the hepatic microcirculation which led to a reduction in tolerance to Ischaemia/Reperfusion (I/R) injury and increased susceptibility to infections. Conversely, our analysis demonstrated no significant variations among patients who received steatotic livers in either category during the first 6 postoperative months which was similar to the results of previous studies. [@JR1800010oa-1] [@JR1800010oa-21] We supposed that differences in the rate of biliary complications were due to the variance between group numbers and this was one of the limiting factors in our study.

Interestingly, it was noticed that the ACR rates were inversely proportional to the degree of steatosis in both categories, being the lowest among the moderate groups (18.8 and 15.8%, respectively) compared with the mild (32 and 32.5%, respectively) and control groups (39.7 and 39%, respectively). However, there was no statistical difference in either category ( *p*  = 0.161 and 0.111, respectively). Cho et al reported that 16.7% of patients who received nonsteatotic grafts had ACR after LT compared with 5.4% of the recipients of steatotic livers. [@JR1800010oa-25] Similarly, Hejlova et al demonstrated a higher rate of ACR among patients who received grafts with no steatosis (6.5%) than among those who received steatotic grafts (4.4%). [@JR1800010oa-26] In addition, Subramanian et al reported that non HCV recipients who received moderate/severe MaS grafts experienced a lower rate of ACR (16.7%) than did the mild (30%) and control (36%) groups. [@JR1800010oa-27] The steatotic livers may have been preconditioned by multiple previous liver insults during the pathogenesis of steatosis. Therefore, these grafts could greatly tolerate the inflammation elicited by the disparity between the donor and recipient.

In addition, no cases in the moderate groups of MaS or MiS had HCV recurrence within the first 6 months post LT but there was not a significant difference when compared with the mild and control groups of each category ( *p*  = 0.423 and 0.366, respectively). Similarly, Botha et al documented that mild and moderate graft MaS has no impact on HCV recurrence after LT for HCV related cirrhosis. Donor age and CIT were the likely risk factors associated with the increase of HCV recurrence. [@JR1800010oa-28]

In our study, the 1, 3, and 5-year patient and graft survival rates were equal in the moderate groups and were 94, 88, and 81%, respectively, in the MaS category and 89, 83, and 76%, respectively, in the MiS category. In comparison with the mild and control groups in each category, no statistical significance was observed.

Some limitations are considered in light of these results. First, the present analysis was derived from a retrospective study. Second, there was a low number of moderate groups of steatosis in both categories which could lead to a *β* error. Finally, in this study, we have demonstrated excellent post LT short and long-term outcomes using grafts with mild and moderate degrees of steatosis with nearly equal results with regard to the type of steatosis.

Additionally, possible advantages of the steatotic grafts have emerged in the form of decreasing the ACR rate postoperatively. Therefore, these grafts should be considered normal grafts and research should now be directed toward the use of severely steatotic livers. Moreover, the D-MELD score is a trustworthy tool for assigning donor--recipient risk factors that can be used safely in marginal graft allocation.

Conclusion
==========

Excellent post LT long-term outcomes using grafts with mild and moderate steatosis were determined. Further studies are needed to evaluate the newly proposed relationship between ACR and steatosis.
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